The Impact of Long-acting Paliperidone in Reducing Hospitalizations and Clinical Severity in Recent Onset Schizophrenia: A Mirror-image Study in Real-world Clinical Setting.

Autor:	Peitl V; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.; Catholic University of Croatia, Zagreb, Croatia., Margetić BA; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.; Catholic University of Croatia, Zagreb, Croatia., Vidrih B; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.; Catholic University of Croatia, Zagreb, Croatia., Karlović D; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.; Catholic University of Croatia, Zagreb, Croatia.
Jazyk:	angličtina
Zdroj:	Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology [Clin Psychopharmacol Neurosci] 2022 Feb 28; Vol. 20 (1), pp. 118-125.
DOI:	10.9758/cpn.2022.20.1.118
Abstrakt:	Objective: Schizophrenia is a debilitating disease that disrupts the lives of many affected individuals and exerts a toll on the health system. Only few studies assessed once-monthly injectable formulation of paliperidone palmitate (PP-1M) and other long-acting antipsychotics in recent onset schizophrenia (ROS). To evaluate whether PP-1M is efficacious in reducing frequency and length of hospitalizations and psychosis symptom severity in patients with ROS. Methods: This mirror-image study included 112 patients, suffering from ROS admitted in a psychiatric ward and successively treated with PP-1M for 1-year. Other psychotic disorders were excluded. We collected socio-demographic data of all subjects included, number and days of hospitalization, as well as Clinical Global Impression-Severity scale (CGI-S) and Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) scores at the initiation and after 1-year of PP treatment. Results: After 1-year PP-1M treatment, mean scores of both CGI and CRDPSS significantly decreased ( p < 0.001), as well as the mean number of hospitalizations ( p = 0.002) and total hospitalization days ( p < 0.001) in comparison with those of the previous year. Conclusion: Our results suggest that PP-1M can be considered as an important therapeutic option in patients with ROS. Its use led to a meaningful reduction in the patient's use of hospital services, as well as a significant clinical improvement of psychotic symptoms in our sample.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu